Novo Nordisk A/S Class B NOVO_B

Could this be what Novo needs to turn things around?

There could be more catalysts for the biotech over the next 18 months.

Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.

Investing.com -- Shares of Eli Lilly and Company (NYSE: LLY) climbed as much as 2.6% before settling up 0.5% after the pharmaceutical giant reported highly positive Phase 2b trial results for its new obesity and type 2 diabetes drug combination. As Lilly’s stock advanced, shares of primary competitor Novo Nordisk slipped 0.3% on the news.

Roche is increasingly looking like a notable contender in this fast-growing area.

Yes, NVO is a stinker but powerhouse names caught in a bearish wind tend to enjoy transitional swings.

A real-world study of 194 patients found those who switched to the daily pill lost an average of 8.8 pounds over 3 months

In a year-long functional magnetic resonance imaging (fMRI) study - a non-invasive method to measure brain activity during specific tasks - CagriSema changed how the brain reacted to tempting, high-calorie foods in areas linked to cravings, pleasure, and self-control in people living with overweight or obesity¹In adults with type 2 diabetes, CagriSema reduced harmful fat around abdominal organs, including the liver and pancreas. Early findings also suggest that bone health was maintained despite

NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.

Novo Nordisk (NVO) concluded the recent trading session at $38.31, signifying a -1.03% move from its prior day's close.

Novo Nordisk (CPSE:NOVO B) entered an exclusive license with Hengrui Pharma for a once-weekly oral GLP-1/GIP dual agonist. Phase 3 CagriSema data delivered new weight management clinical results that add another late-stage asset to Novo Nordisk’s pipeline. The CHMP issued a positive opinion backing Sogroya for idiopathic short stature and supported FREHEMGO for hemophilia A patients. The Hengrui oral GLP-1/GIP deal and new trial wins tell only part of the Novo Nordisk story. We have also...

Zepbound 15 mg was associated with 4.5 percentage points more weight loss than Wegovy HD.

Eli Lilly is growing faster than any other mega-cap drugmaker, but a pipeline drug still awaiting approval and falling U.S. prices are pulling the stock in opposite directions. The outcome of that tension shapes whether shares have another 20% to climb or stall near today's levels.

An indirect comparison favored Foundayo, but no head-to-head trial has established superiority over oral semaglutide.

Novo Nordisk Drops Big Ozempic Finding From 630,000-Patient Study

The Danish drugmaker agreed to pay up to $2.6 billion for rights to Hengrui’s once-weekly oral GLP-1/GIP candidate as it races to rebuild its post-Wegovy pipeline.